| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11239-007-0104-Y |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s11239-007-0104-y |
| P698 | PubMed publication ID | 17906972 |
| P5875 | ResearchGate publication ID | 5937910 |
| P2093 | author name string | Lawrence J Lesko | |
| Brian F Gage | |||
| P2860 | cites work | American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy | Q56986988 |
| Warfarin-induced impairment of cortical bone material quality and compensatory adaptation of cortical bone structure to mechanical stimuli | Q57565690 | ||
| Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications | Q63241969 | ||
| Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences | Q67728153 | ||
| Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe | Q70552798 | ||
| Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy | Q73006002 | ||
| A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial | Q73180786 | ||
| Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy | Q73286594 | ||
| Genetic modulation of oral anticoagulation with warfarin | Q73322523 | ||
| Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of Monitoring | Q73468973 | ||
| Genetic association between sensitivity to warfarin and expression of CYP2C9*3 | Q73834859 | ||
| Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes | Q77590824 | ||
| A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance | Q79365564 | ||
| Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records | Q80031569 | ||
| The genetics of vitamin K antagonists | Q80098649 | ||
| Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin | Q82627288 | ||
| A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk | Q24817078 | ||
| Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin | Q28171104 | ||
| Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database | Q28188181 | ||
| Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 | Q28242581 | ||
| Identification of the gene for vitamin K epoxide reductase | Q28242592 | ||
| Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study | Q29614197 | ||
| Managing oral anticoagulant therapy | Q30649541 | ||
| Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing | Q32049910 | ||
| Evaluation of warfarin initiation regimens in elderly inpatients | Q34000986 | ||
| Warfarin therapy for an octogenarian who has atrial fibrillation | Q34187672 | ||
| Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. | Q34283903 | ||
| CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis | Q34394876 | ||
| Common VKORC1 and GGCX polymorphisms associated with warfarin dose | Q34417386 | ||
| Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose | Q34423204 | ||
| Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. | Q34487341 | ||
| Flexible induction dose regimen for warfarin and prediction of maintenance dose | Q34548246 | ||
| Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation | Q34630189 | ||
| A new regimen for starting warfarin therapy in out-patients | Q35802527 | ||
| Genetic-based dosing in orthopedic patients beginning warfarin therapy. | Q35989429 | ||
| A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism | Q37360472 | ||
| Maternal and fetal sequelae of anticoagulation during pregnancy | Q40280362 | ||
| Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention | Q40844377 | ||
| Major bleeding after hospitalization for deep-venous thrombosis. | Q41703407 | ||
| Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group | Q42287205 | ||
| Aging and the anticoagulant response to warfarin therapy | Q43672961 | ||
| Interindividual variability in sensitivity to warfarin--Nature or nurture? | Q43705893 | ||
| Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin | Q43820514 | ||
| The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin | Q43917059 | ||
| Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy | Q43942672 | ||
| Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity | Q44680862 | ||
| The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon | Q44884452 | ||
| Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans | Q45004299 | ||
| Tailoring warfarin induction doses to reflect individual and disease-specific factors. | Q45253321 | ||
| The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen | Q46537717 | ||
| Population variation in VKORC1 haplotype structure | Q46899663 | ||
| Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis | Q47351547 | ||
| Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. | Q51975669 | ||
| Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. | Q52005905 | ||
| Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. | Q52106400 | ||
| Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty's protocol. | Q53339996 | ||
| Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. | Q53358927 | ||
| A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. | Q53991290 | ||
| P433 | issue | 1 | |
| P921 | main subject | (RS)-warfarin | Q407431 |
| P304 | page(s) | 45-51 | |
| P577 | publication date | 2007-10-01 | |
| P1433 | published in | Journal of Thrombosis and Thrombolysis | Q15766541 |
| P1476 | title | Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues | |
| P478 | volume | 25 |
| Q37926276 | "The end of good luck''--long-term survival without anticoagulation: a case report and review of the literature |
| Q90068670 | A Simple Formula for Predicting the Maintenance Dose of Warfarin with Reference to the Initial Response to Low Dosing at an Outpatient Clinic |
| Q37088955 | A cardiovascular phenotype in warfarin-resistant Vkorc1 mutant rats |
| Q36835176 | A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose |
| Q43857194 | A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms |
| Q37380399 | A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity |
| Q43217456 | ARMS test for diagnosis of CYP2C9 and VKORC1 mutation in patients with pulmonary embolism in Han Chinese |
| Q43926562 | Acenocoumarol Pharmacogenetic Dosing Algorithms and Their Application in Two Bulgarian Patients with Low Anticoagulant Requirements |
| Q33666570 | An Assessment of Osteoporotic Conditions among Users and Non-Users of Warfarin: A Case-Control Study |
| Q28544983 | Analysis of pharmacogenomic variants associated with population differentiation |
| Q37219549 | Anticoagulation: where we are and where we need to go. |
| Q37580473 | Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends |
| Q35030197 | Assessment of the pharmacogenomics educational needs of pharmacists. |
| Q42939949 | Benefits of pharmacogenomics in drug development-earlier launch of drugs and less adverse events |
| Q35051893 | Bioinformatics challenges for personalized medicine |
| Q34287019 | Chapter 11: challenges in and principles for conducting systematic reviews of genetic tests used as predictive indicators |
| Q33745957 | Characteristics of ambulatory anticoagulant adverse drug events: a descriptive study |
| Q40077202 | Characterization of the Asian Phenotype - An Emerging Paradigm with Clinicopathological and Human Research Implications |
| Q27008360 | Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing |
| Q34834319 | Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model |
| Q36626572 | Development and evaluation of a pharmacogenomics educational program for pharmacists |
| Q34154939 | Drug-gene interactions: inherent variability in drug maintenance dose requirements |
| Q41535274 | Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke |
| Q28276605 | Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis |
| Q48905886 | Effect of gene polymorphims on the warfarin treatment at initial stage. |
| Q45880221 | Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy |
| Q64237015 | Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy |
| Q61449022 | Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy |
| Q27026134 | Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis |
| Q33912911 | Evaluation of risk factors in patients with vitamin K-dependent coagulopathy presumed to be caused by exposure to brodifacoum |
| Q43201531 | Exciton Primer-mediated SNP detection in SmartAmp2 reactions. |
| Q34994877 | Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. |
| Q38897899 | Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism |
| Q39514336 | Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population |
| Q37777419 | Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk |
| Q37235860 | Genetic testing for warfarin therapy initiation |
| Q36813817 | Genetic variation and haplotype structure of the gene Vitamin K epoxide reductase complex, subunit 1 in the Tamilian population. |
| Q37126654 | Genetic variations and their influence on risk and treatment of venous thrombosis |
| Q35021027 | Genetic warfarin dosing: tables versus algorithms. |
| Q38292930 | Genomic architecture of pharmacological efficacy and adverse events |
| Q37347806 | Genomics: risk and outcomes in cardiac surgery |
| Q37423924 | Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, Brazil |
| Q64067200 | Impact of a variable number tandem repeat in the CYP2C9 promoter on warfarin sensitivity and responsiveness in Jordanians with cardiovascular disease |
| Q60935144 | Impact of and Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy |
| Q64111486 | Impact of gene polymorphism on the initiation and maintenance phases of warfarin therapy in Chinese patients undergoing heart valve replacement |
| Q37174998 | Impact of genetic variation on perioperative bleeding |
| Q35757323 | Impact of polymorphisms of the GGCX gene on maintenance warfarin dose in Chinese populations: Systematic review and meta-analysis |
| Q40568462 | Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol |
| Q35219654 | Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry |
| Q39471514 | Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients |
| Q42679670 | Informed consent for blood tests in people with a learning disability |
| Q37345384 | Inter and intra ethnic variation of vitamin K epoxide reductase complex and cytochrome P450 4F2 genetic polymorphisms and their prevalence in South Indian population |
| Q37425137 | Measuring quality of oral anticoagulation care: extending quality measurement to a new field. |
| Q53156908 | Minor bleeds alert for subsequent major bleeding in patients using vitamin K antagonists. |
| Q37419810 | Novel anticoagulants and the future of anticoagulation |
| Q36475190 | Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects |
| Q33983987 | Only connect: personal genomics and the future of American medicine |
| Q84149008 | Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up |
| Q34790566 | Pathway analysis of genome-wide data improves warfarin dose prediction |
| Q37867275 | Patient factors that influence warfarin dose response |
| Q28082746 | Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine |
| Q41960992 | Personalized healthcare in clotting disorders |
| Q38027568 | Personalized medicine policy challenges: measuring clinical utility at point of care |
| Q43144906 | Personalizing health care--is this the right time for warfarin? |
| Q37768070 | Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. |
| Q26859221 | Pharmacogenetics and anaesthesia: the value of genetic profiling |
| Q24289489 | Pharmacogenetics education in British medical schools |
| Q57302675 | Pharmacogenetics of Adverse Drug Reactions |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q38274487 | Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation. |
| Q91740942 | Pharmacogenomics In Pharmacy Practice: Current Perspectives |
| Q27001573 | Pharmacogenomics discovery and implementation in genome-wide association studies era |
| Q38116753 | Pharmacogenomics of anti-platelet and anti-coagulation therapy |
| Q37989489 | Prediction of warfarin dose: why, when and how? |
| Q33990441 | Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics. |
| Q33523960 | Rapid genotyping of single nucleotide polymorphisms influencing warfarin drug response by surface-enhanced laser desorption and ionization time-of-flight (SELDI-TOF) mass spectrometry |
| Q36252524 | Relating human genetic variation to variation in drug responses |
| Q37169126 | Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy |
| Q37472933 | Role of pharmacogenomics in drug discovery and development |
| Q33978811 | Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans. |
| Q28553937 | The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study |
| Q48665970 | The Impact of Gene Polymorphisms on Anticoagulation Control With Warfarin. |
| Q53695415 | The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians. |
| Q37812378 | The assessment of stroke and bleeding risk in atrial fibrillation: where are we now? |
| Q37664619 | The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population. |
| Q38750444 | The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). |
| Q37071087 | The largest prospective warfarin-treated cohort supports genetic forecasting |
| Q35071798 | The use of warfarin for DVT prophylaxis following hip and knee arthroplasty: how often are patients within their target INR range? |
| Q90053693 | Therapeutic strategies for thrombosis: new targets and approaches |
| Q37264536 | Use of plasmid-derived external quality control samples in pharmacogenetic testing |
| Q38411840 | Using new oral anticoagulants in patients undergoing major orthopedic surgery |
| Q46238853 | VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients |
| Q41968877 | VKORC1 pharmacogenomics summary |
| Q47345423 | VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study. |
| Q33813830 | Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing |
| Q38983845 | Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients. |
| Q38897904 | Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients |
| Q43178551 | Variant VKORC1 and CYP2C9 alleles in patients with diffuse alveolar hemorrhage caused by oral anticoagulants |
| Q45749835 | Vitamin K epoxide reductase complex 1 (VKORC1) haplotypes in healthy Hungarian and Roma population samples. |
| Q46421340 | Warfarin and pharmacogenomic testing: the case for restraint |
| Q31131437 | Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model |
| Q34977531 | Warfarin dosage response related pharmacogenetics in Chinese population |
| Q30275196 | Warfarin genotyping with hybridization-induced aggregation on a poly(ethylene terephthalate) microdevice. |
| Q33561482 | Warfarin pharmacogenomics |
| Q35155651 | Warfarin toxicity and individual variability-clinical case |
| Q81743327 | [General concepts and study methods in pharmacogenetics] |
Search more.